[
  {
    "ts": "2026-01-12T12:00:00+00:00",
    "headline": "Boston Scientific Announces Agreement to Acquire Valencia Technologies Corporation",
    "summary": "Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on the development and commercialization of innovative solutions to treat bladder dysfunction. The company's eCoin® System is an implantable tibial nerve stimulation (ITNS) device for the treatment of urge urinary incontinence (UUI), a common symptom of overactive bladder (OAB).",
    "url": "https://finance.yahoo.com/news/boston-scientific-announces-agreement-acquire-120000004.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "877b4a69-a62d-3810-9c96-bbf2792a2650",
      "content": {
        "id": "877b4a69-a62d-3810-9c96-bbf2792a2650",
        "contentType": "STORY",
        "title": "Boston Scientific Announces Agreement to Acquire Valencia Technologies Corporation",
        "description": "",
        "summary": "Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on the development and commercialization of innovative solutions to treat bladder dysfunction. The company's eCoin® System is an implantable tibial nerve stimulation (ITNS) device for the treatment of urge urinary incontinence (UUI), a common symptom of overactive bladder (OAB).",
        "pubDate": "2026-01-12T12:00:00Z",
        "displayTime": "2026-01-12T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/e1efff8c1827a2416164ff633f6854d6",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tEzXUzk4uQBJUN9VCLa3LQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/e1efff8c1827a2416164ff633f6854d6.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iuWNFOM6Te.RxBERx3Cnpw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/e1efff8c1827a2416164ff633f6854d6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/boston-scientific-announces-agreement-acquire-120000004.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/boston-scientific-announces-agreement-acquire-120000004.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-12T13:00:00+00:00",
    "headline": "Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones",
    "summary": "Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a corporate update and outlined upcoming development milestones for NXT-41x, its next-generation antibiotic-eluting biomatrix program in plastic and reconstructive surgery. NXT-41x is El",
    "url": "https://finance.yahoo.com/news/elutia-reports-preliminary-fourth-quarter-130000380.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "d3982c7c-be03-3be5-9077-be21ba51e1fe",
      "content": {
        "id": "d3982c7c-be03-3be5-9077-be21ba51e1fe",
        "contentType": "STORY",
        "title": "Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones",
        "description": "",
        "summary": "Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a corporate update and outlined upcoming development milestones for NXT-41x, its next-generation antibiotic-eluting biomatrix program in plastic and reconstructive surgery. NXT-41x is El",
        "pubDate": "2026-01-12T13:00:00Z",
        "displayTime": "2026-01-12T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/acb8ce730ecd9f3870468a11e1c1300d",
          "originalWidth": 2048,
          "originalHeight": 455,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UZDWpsnvZMiblfXugK_fkw--~B/aD00NTU7dz0yMDQ4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/acb8ce730ecd9f3870468a11e1c1300d.cf.webp",
              "width": 2048,
              "height": 455,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vHtfmG3ERYsDP0feqscEWg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/acb8ce730ecd9f3870468a11e1c1300d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/elutia-reports-preliminary-fourth-quarter-130000380.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/elutia-reports-preliminary-fourth-quarter-130000380.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ELUT"
            },
            {
              "symbol": "BSX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]